Centauri Therapeutics Ltd., an immunotherapy company with a platform technology applicable across a wide range of therapeutic indications, has been awarded a £1 million grant by PACE (Pathways to Antimicrobial Clinical Efficacy), an initiative focused on early-stage antimicrobial drug and diagnostic discovery. The funding will support the continued development of Centauri’s Alphamer technology, in this case targeting Gram-negative bacteria including Multi-Drug Resistant (MDR) bacterial strains. ...